After finishing at $0.38 in the prior trading day, IGC Pharma Inc (AMEX: IGC) closed at $0.34, down -8.91%. In other words, the price has decreased by -$0.0337 from its previous closing price. On the day, 2418594 shares were traded.
Ratios:
Our goal is to gain a better understanding of IGC by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.83 and its Current Ratio is at 1.85. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.03.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IGC now has a Market Capitalization of 21.96M and an Enterprise Value of 20.96M. For the stock, the TTM Price-to-Sale (P/S) ratio is 18.00 while its Price-to-Book (P/B) ratio in mrq is 2.43. Its current Enterprise Value per Revenue stands at 17.23 whereas that against EBITDA is -1.90.
Stock Price History:
Over the past 52 weeks, IGC has reached a high of $0.50, while it has fallen to a 52-week low of $0.25. The 50-Day Moving Average of the stock is 0.3048, while the 200-Day Moving Average is calculated to be 0.3226.
Shares Statistics:
The stock has traded on average 419.97K shares per day over the past 3-months and 664.62k shares per day over the last 10 days, according to various share statistics. A total of 63.73M shares are outstanding, with a floating share count of 56.73M. Insiders hold about 10.98% of the company’s shares, while institutions hold 3.87% stake in the company. Shares short for IGC as of Feb 29, 2024 were 910.73k with a Short Ratio of 2.17, compared to 961.25k on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 1.43% and a Short% of Float of 1.52%.
Earnings Estimates
Its stock is currently analyzed by 1 different market analysts. The consensus estimate for the next quarter is -$0.04, with high estimates of -$0.04 and low estimates of -$0.04.
Analysts are recommending an EPS of between -$0.22 and -$0.22 for the fiscal current year, implying an average EPS of -$0.22. EPS for the following year is -$0.16, with 1 analysts recommending between -$0.16 and -$0.16.
Revenue Estimates
Based on 1 analysts’ estimates, the company’s revenue will be $1.4M in the next fiscal year. The high estimate is $1.4M and the low estimate is $1.4M. The average revenue growth estimate for next year is up 12.90% from the average revenue estimate for this year.
